Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iodine-131 Anti-B1 Antibody for Relapsed/Transformed B-Cell Lymphoma
NCT00950755Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 1998
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tositumomab in B cell lymphoma, sponsored by GSK. Primary endpoints: Response Rate at 2 years, Confirmed Response Rate at 2 years and 2 more. Started Jun 1998; status: completed.
02
Drugs
tositumomab
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT00950755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950755.